Maharashtra local bodies polls likely by April 2025 if SC decides on OBC quota Bawankule

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California. A poster titled “ CD38-SADA, a S elf- A ssembling and D is- A ssembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma ” characterizes the selective binding of CD38-SADA to DOTA-chelated lanthanide metals and high-avidity binding to CD38, a tumor specific antigen overexpressed across a range of lymphoma cells. Data from this poster demonstrate anti-tumor efficacy of CD38-SADA when used with Lutetium 177 (Lu 177 )-DOTA in a two-step approach to pre-targeted radioimmunotherapy (“PRIT”). Tumor responses in a xenograft mouse model were rapid and dose-dependent, further supporting the clinical development of CD38-SADA PRIT in patients with CD38-positive lymphoid malignancies. “This preclinical analysis provides important insights into the unique pharmacology of CD38-SADA and its therapeutic potential for NHL,” said Brian H. Santich, Ph.D., the lead author and co-inventor of the SADA PRIT technology platform. “The anti-tumor efficacy positively correlated with increasing doses of Lu 177 -DOTA and CD38-SADA, which informed the study design and initial dosing regimen of our Trial 1201 in patients with NHL.” In addition, Y-mAbs presents a trial-in-progress poster from its ongoing Phase 1 (Trial 1201) clinical study evaluating the safety and tolerability of CD38-SADA PRIT with Lu 177 -DOTA in adults with relapsed or refractory NHL. Trial 1201 is a first-in-human, dose-escalation, open-label, multicenter study composed of two parts. Part A includes dose escalation of the CD38-SADA bispecific fusion protein to define the optimal safe dose of the CD38-SADA protein, the administration interval between CD38-SADA and Lu 177 -DOTA, and the Lu 177 -DOTA dose for tumor imaging. In Part B, dose escalation of Lu 177 -DOTA will establish the optimal therapeutic dose of the radioactive payload. For each part, the escalation is based on a 3+3 trial design of 4 planned dose levels. “We are pleased to share the details of this Phase 1 clinical trial, which is investigating a potentially transformative approach to pre-targeted radioimmunotherapy for patients with relapsed and refractory NHL,” said Vignesh Rajah, MBBS, DCH, MRCP (UK), Chief Medical Officer. “This is our second clinical program evaluating the SADA PRIT technology platform and our first in hematological malignancies.” The abstract details are below: Abstract Title: “ CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma” Format : Poster Presentation, ID: 1599 Date and Time: Saturday, December 7, 2024, 5:30 PM-7:30 PM Abstract Title: “ CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial” Format : Poster Presentation, ID: 4434.1 Date and Time: Monday, December 9, 2024, 6:00 PM-8:00 PM Researchers at Memorial Sloan Kettering Cancer Center (MSK), including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. About CD38-SADA PRIT CD38-SADA is a bispecific fusion protein that tightly binds to the CD38 antigen and to select radionuclides chelated to tetraxetan (or “DOTA”). CD38-SADA contains a p53-derived domain that drives the self-assembly of CD38-SADA tetramers, which possess four distinct binding sites for CD38. In the first step of pre-targeted radiotherapy, non-radiolabeled-CD38-SADA tetramers are infused and bind with high avidity to CD38-positive tumors, while unbound CD38-SADA disassembles into low molecular weight monomers that are removed by the kidney. The second infusion delivers the “radioactive payload,” which binds to the CD38-SADA on tumor cells for localized irradiation. CD38-SADA PRIT with Lutetium 177 (Lu 177)-DOTA is now under clinical investigation in Trial 1201 (NCT05994157). Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, use of cash and cash equivalents and DANYELZA product revenue and sufficiency of cash resources and related assumptions; expectations with respect to the Company’s future financial performance; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; expectations with respect to the Company’s plans and strategies, development, regulatory, commercialization and product distribution plans, including the timing thereof; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT technology and potential benefits and applications thereof; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s or its partners’ regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture as well as regulatory submissions; the Company’s ability to enter into new partnerships or to recognize the anticipated benefits from its existing partnerships; risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. SADA®, SADA PRIT®, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. Investor Contact: Courtney Dugan VP, Head of Investor Relations cdu@ymabs.com

The Friday college basketball slate is stacked and Underdog Fantasy promo code BETFPB guarantees a 50% deposit bonus up to $1,000 to all new customers. Wager on college basketball props for all available games including: Simply register using our Underdog Fantasy promo code BETFPB , then make an initial deposit. That investment will be matched 50% of the way up to $1,000. If you seek an alternative to sportsbooks or you aren't in a legal betting state, Underdog is for you. It's widely available and offers the chance to combine multiple Higher or Lower (Over/Under) picks into a single entry, just like a parlay. Underdog also has live props throughout the game. Registering by clicking one of our links or entering Underdog Fantasy promo code BETFPB while signing up means qualifying for a bonus up to $1,000 once you register and make an initial deposit, which Underdog matches 50% of the way. Note: This Underdog Fantasy bonus is available in AL, AK, AZ, AR, CA, CO, DC, FL, GA, IL, IN, KS, KY, MA, MN, MS, NE, NM, NY, NC, ND, OK, OR, RI, SC, SD, TX, UT, VT, VA, WI, WY & All Canadian Provinces except ON. How to register for Underdog Fantasy All new customers can earn up to $1,000 in bonuses to play with at Underdog. Follow the steps listed below to claim the promo: The bonus will land in your account within 72 hours and must be used within 60 days. This is a great way to test out the platform. Underdog Fantasy is available in over 30 states including many without legal sports betting. If you live in an eligible state, you can take full advantage of the platform and sign up to play fun daily fantasy contests. In the run up to Thanksgiving, the college basketball slate is packed with holiday tournaments and wall-to-wall action. As a result, there are several appetizing games every day and perhaps none more so than No. 17 Arizona vs. No. 12 Duke (10:30 p.m. ET on ESPN2). The schedule includes: Duke is 3-1 but is playing its first game away from home while Arizona is 2-0 and remains in the friendly confines of the McKale Center for this one. Arizona is a slim 1.5-point favorite with the total at 161 points at DraftKings. Claim $1,000 deposit bonus from Underdog Fantasy Each game houses plenty of college football player props and for each one, bettors must choose Higher or Lower on the total set by Underdog. This includes points, rebounds, assists, stat combinations and more. From there, make between 2 and 8 selections to put into an entry, with the payouts increasing with each added selection. For entries of three selections or more, a 'flex' option is available that will pay out a portion of winnings even if one of your selections falls short. Please note that college football props may be limited to select states, so check your local listings on the Underdog app. There are a variety of contests that users can enter on the Underdog Fantasy platform. These are different game styles that let users test their knowledge in different ways. After you take advantage of the Underdog Fantasy promo bonus using the code BETFPB , you will see all of these different game types offered to you. There are two main contests that are used for contests at Underdog Fantasy. They are the Pick ‘Em contest and the Draft contest. They work as follows. You must be over 21 to play. Gambling Problem? Call 1-800-522-4700. 1-800 GAMBLER. Brian Sausa is a New York-based content creator for Catena Media with an extensive betting history and several years of iGaming industry experience. A journalism graduate with a ranging sports background, Brian’s previous employment includes the flagship sites for multiple professional leagues including the MLB and NHL. Get local news delivered to your inbox!Zelensky insists on a 'just peace' at Trump Paris meeting

TAMPA, Fla. (AP) — The Tampa Bay Buccaneers are determined to not get ahead of themselves. Sunday’s 30-7 rout of the New York Giants began a six-game, regular season-ending stretch in which the Bucs (5-6) will face five opponents that currently have losing records. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Bride, groom, spy: India’s wedding detectives

TAMPA, Fla. (AP) — The Tampa Bay Buccaneers are determined to not get ahead of themselves. Sunday’s 30-7 rout of the New York Giants began a six-game, regular season-ending stretch in which the Bucs (5-6) will face five opponents that currently have losing records. The victory coming out of the team’s bye week stopped a four-game skid and moved the three-time defending NFC South champions within one game of first-place Atlanta in the division. The Falcons swept the season series, so the Bucs essentially trail the Falcons by two games with six remaining. They’re in a good position to chase their fifth consecutive playoff berth, but can hardly assume they’ll benefit from having an easy remaining schedule. “We’re hoping it builds confidence. We have belief that we’re still sitting and controlling our own destiny,” quarterback Baker Mayfield said of beating the Giants. “But it’s not just going to happen,” Mayfield added. “So, we have to take it one week at a time. And you find the recipe for success within your work week. ... You try to emulate that week after week and continue to build it.” The Los Angeles Chargers, who entered Monday night’s game against Baltimore at 7-3, are the only opponent remaining on Tampa Bay’s schedule that currently has a winning record. The Bucs will face division rival Carolina (3-8) twice in the next six weeks. They’ll also host Las Vegas (2-9) and New Orleans (4-7) and play the Chargers and Dallas Cowboys (4-7) on the road. “We can’t get comfortable,” rookie running back Bucky Irving said. “We just got to keep our foot on the gas and keep running.” The offense continues to put up big numbers, finishing with 450 yards against the Giants. It’s the fifth time Tampa Bay has gained more than 400 yards this season. The Bucs have now scored 30-plus points six times, second in the NFL behind Buffalo’s eight. There wasn’t a lot to fault in the team’s performance against the Giants, although coach Todd Bowles said both the offense and defense could have been done a better job closing out the game late. “For the most part we executed on both sides of the football,” Bowles said. “Still like to have finished the game a little better, but they came back (from the bye week) mentally tougher, and they came ready to play.” Irving averaged more than 7 yards per carry in rushing for 87 yards on 12 attempts. He also had six receptions for 64 yards, finishing with a season-high 151 yards from scrimmage. Just when it looked as if the defense was beginning to trend the right way health-wise, the Bucs lost safety Jordan Whitehead (pectoral) and linebacker Joe Tryon-Shoyinka (ankle) to injuries on Sunday. Bowles said Monday he was still awaiting an update on the severity of Whitehead’s injury. Tryon-Shoyinka has an ankle sprain. LT Tristan Wirfs (knee) sat out against the Giants and his status will be evaluated as the week progresses. 11. With wide receiver Mike Evans back on the field after missing three games with a hamstring injury, Mayfield completed passes to 11 different players, tying a team record. “He obviously changed the game, even when he's not getting the ball,” Mayfield said. “It's huge that we have him in.” At Carolina, the second of three consecutive games vs. last-place teams the Bucs will face during their stretch run. They’ll also host the Panthers on Dec. 29. “It’s an NFC South battle, and all of them are going to be hard. None of them are going to be easy,” Bowles said. “I think (coach) Dave (Canales) has done an excellent job taking on that team and it’s taking over his personality right now,” Bowles added. “They’re playing pretty good football. ... It’s going to be a tough battle.” AP NFL: https://apnews.com/hub/nflPITTSBURGH , Dec. 2, 2024 /PRNewswire/ -- The Board of Directors of Wesco International (NYSE: WCC) today declared a quarterly cash dividend on all of the issued and outstanding shares of common stock, in an amount equal to $0.4125 per share. The dividend is payable on December 31, 2024 to the holders of record of the common stock at the close of business on December 13, 2024 . In addition, the Board of Directors declared cash dividends on the company's 10.625% Series A Fixed-Rate Reset Cumulative Perpetual Preferred Stock for the period October 1, 2024 through December 31, 2024 . The dividend is $664.0625 per preferred share, or $0.6640625 per depository share, and is payable on December 31, 2024 to holders of record at the close of business on December 13, 2024 . About Wesco Wesco International (NYSE: WCC) builds, connects, powers and protects the world. Headquartered in Pittsburgh, Pennsylvania , Wesco is a FORTUNE 500 ® company with $22 billion in annual sales and a leading provider of business-to-business distribution, logistics services and supply chain solutions. Wesco offers a best-in-class product and services portfolio of Electrical and Electronic Solutions, Communications and Security Solutions, and Utility and Broadband Solutions. The Company employs approximately 20,000 people, partners with the industry's premier suppliers, and serves thousands of customers around the world. With millions of products, end-to-end supply chain services, and leading digital capabilities, Wesco provides innovative solutions to meet customer needs across commercial and industrial businesses, contractors, government agencies, educational institutions, telecommunications providers, and utilities. Wesco operates nearly 800 branches, warehouses and sales offices in more than 50 countries, providing a local presence for customers and a global network to serve multi-location businesses and global corporations. Contact Information Investor Relations Will Ruthrauff Director, Investor Relations 484-885-5648 Corporate Communications Jennifer Sniderman Vice President, Corporate Communications 717-579-6603 View original content to download multimedia: https://www.prnewswire.com/news-releases/wesco-declares-quarterly-dividend-on-common-stock-and-preferred-stock-302319822.html SOURCE Wesco International

Deutsche Bank appointed as depositary bank for the sponsored American Depositary Receipt program of Pony AI Inc.The blistering rally in gold augurs ill for the power of the dollarLAGOS – The federal government, on Tuesday in Lagos, disclosed that ongoing efforts and activities of partner agencies to reduce the Out-Of-School-Children in Nigeria has impacted a total of two million beneficiaries. Dr Maruf Tunji Alausa, the Honorable Minister Of Education, disclosed this at the opening ceremonies of the ongoing three-day summit of the Basic Education In Nigeria Bootcamp (Ben-B) summit held in Lagos with the theme: “Improving Access to Inclusive Quality Education for All Children in Nigeria: Addressing the Challenges of Out-of-School Children”. The Minister in his message delivered by Dr (Mrs) Folake Olatunji-David, Director of Basic Education in the Federal Ministry of Education said the implementation of policies through the activities of four of its agencies and bilateral development partners supported by the take-off of the Almajiri and Out-of-School Commission is making positive impacts as part of the system-wide policy with a huge impact on Out-of-­School Children. He said, “The Federal Ministry of Education is set for and indeed has commenced the implementation of key policies distilled with system-wide outcomes and their deep practical effects in the life of this Administration.” He said the policies captured by the Data Repository, Out-of-School Children Education, Teacher Training & Development, and Skills Development and Acquisition (DOTS) when implemented, will succeed in connecting the dots for the improvement of the overall education system in Nigeria. Emphasising the importance of data at the summit organised by the Federal Ministry of Education (FMoE), the Minister lamented the uncoordinated data repository in the country, saying unverifiable data has resulted in the citing of different figures for Out-Of-School-Children by governments and various bilateral partners. He acknowledged the place of quality teachers as pivotal in achieving policies on quality education and skilling, saying extant policies on teacher’s welfare, support and development would be reviewed for a more effective implementation. He added, “As we strive to ensure unfettered access to nine (9) years of formal basic education, we recognize the importance of free, Universal Basic Education for every Nigerian child of school-going age. Our collective efforts aim to reduce drastically the incidence of drop-out from the formal school system, through improved relevance, quality and efficiency.” Governor Babajide Sanwo-Olu, in a keynote address, said the place of education at all levels of the renewed hope agenda of President Bola Tinubu will create a befitting future for children and, in effect, have a positive impact on the nation’s social, economic, technology and political advancement. The Governor, represented by Hon. Jamiu Alli-Balogun, the Commissioner For Primary and Basic Education, said the outcomes will include sustainable plans, policies, and regulations that are visible, accessible, practical-oriented and cost-effective. He stressed the commitment of the state government to education and technology as one of the core THEME+ agenda of Lagos State, saying it has created and leveraged better education performance with a technology-driven approach. “The state had committed more resources in the establishment of new schools, skills acquisition centres, continuous rehabilitation of schools, restructuring of school plants, recruitment of professionally qualified teachers, provision of teaching materials, deployment of technology, teachers’ capacity building and motivation across the board. “In Lagos State, we have come up with various strategies to combat out-of-school children through aggressive enrollment drives and project zero, which reduces learning poverty and equally returning children found on the street to school,” he said. He urged stakeholders in the education sector to change the current approaches to build a world where every child survives, thrives, and has the power to shape their future. Prof Pai Obanya of the Institute of Education at the University of Ibadan (UI), the lead paper presenter, urged stakeholders to change the current notion about the profession, saying “Teaching is not as simply telling, but mainly as guiding, continuous assessment in place of continual testing, support tools from local and other sources,” he advocated. Delivering a paper titled: “Improving Access to Inclusive Quality Education for all Children in Nigeria: Addressing the Challenge of Out-Of-School-Children”, Prof Obanya called for disaggregated data and enhanced inter-agency synergy, the institution of systematic monitoring and targeted funding as part of measures to put the nation’s education back on track and tackle the Out-Of-School-Children menace. He urged the managers of the education sector to revisit and be guided by the implementation guidelines on Universal Basic Education (UBE),1999, UBE Roadmap, 2015 and the National Teacher Education Policy to reset the sector for sustainable growth amd development. Purpose Of the Summit Dr. Olatunji-David, represented by Mrs Joy Onoja, Director, Public asic Education Education said the main objectives of the Bootcamp are to: Assemble Basic Education stakeholders to deliberate on Policy, practice and implementation gaps facing the sub-sector. Ensure responsiveness of state ministries of Education (SMoEs) in compliance with National Education Policy decisions and programmes. Harmonize and coordinate resources and activities in the Basic Education sub-sector towards the achievement of national goals and aspirations. Monitor the progress of states and ensure reporting to the Federal Ministry of Education for proper coordination. The summit will review the implementation status, that is assess the extent to which recommendations have been implemented, identify best practices, share successful strategies and experience, address implementation gaps, refine strategies, foster collaboration, inform policy decisions, monitor progress and identify resource gaps.

Man extradited to Victoria over crash that killed paramedicHelping to drown out the noise

California Democrats open special session to Trump-proof state priorities

Piers Morgan leads well-wishes for Michail Antonio after horror crash trapped him in his Ferrari for 45 minutes

Halliburton Co. stock rises Monday, still underperforms market

Trump isn't back in office but he's already pushing his agenda and negotiating with world leadersCNN wants the North Carolina lieutenant governor's defamation lawsuit against it thrown out

GREENSBORO, N.C. (AP) — Kenyon Giles scored 25 points as UNC Greensboro beat N.C. A&T 67-55 on Saturday. Giles had five rebounds for the Spartans (5-4). Donovan Atwell scored 15 points and added five rebounds. Jalen Breath shot 1 of 6 from the field and 8 for 8 from the line to finish with 10 points, while adding 10 rebounds. The Aggies (3-6) were led by Ryan Forrest, who posted 18 points and eight rebounds. Camian Shell added 15 points for N.C. A&T. Jahnathan Lamothe finished with 13 points and two steals. Atwell scored 11 points in the first half and UNC Greensboro went into the break trailing 36-35. Giles scored 15 points in the second half to help lead UNC Greensboro to a 12-point victory. NEXT UP UNC Greensboro's next game is Saturday against North Florida on the road, and N.C. A&T visits Virginia Tech on Thursday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .